Skip to main content

New molecular targets and proof-of-concept therapies for Autism Spectrum Disorders

Project description

Shrinking the autism research gap

Diagnosed before age 3 based on behavioural cues, autism is a major multifactorial neurodevelopmental disorder, affecting 1 in 100 child births worldwide. There is no cure and what is more, there is no one size fits all approach to autism management. The EU-funded THERAUTISM project will aim to shrink the autism research gap to expose the common molecular and cellular dysfunctions underlying autism-related behaviours. It will also investigate the possibility for a safe gene therapy vector – after it takes into account the properties of a new protein function to restore this new target and rescue social deficits in different preclinical models of autism. The aim is to validate new molecular therapeutic targets.

Field of science

  • /medical and health sciences/medical biotechnology/genetic engineering/gene therapy

Call for proposal

ERC-2019-STG
See other projects for this call

Funding Scheme

ERC-STG - Starting Grant

Host institution

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Address
Rue Michel Ange 3
75794 Paris
France
Activity type
Research Organisations
EU contribution
€ 1 499 025

Beneficiaries (1)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 1 499 025
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations